<DOC>
	<DOCNO>NCT00338949</DOCNO>
	<brief_summary>This study evaluate effectiveness ziprasidone treatment versus treatment standard atypical antipsychotic drug improve insulin sensitivity reduce excess abdominal fat storage people schizophrenia risk diabetes .</brief_summary>
	<brief_title>Ziprasidone Improving Insulin Sensitivity People With Schizophrenia Who Are Risk Diabetes</brief_title>
	<detailed_description>People schizophrenia often lead sedentary lifestyle people without disease , frequently treat antipsychotic medication cause weight gain . Combined , factor produce increase risk metabolic syndrome , lead heart disease type 2 diabetes . Characteristics metabolic syndrome include carry excess weight around abdominal region ; high blood pressure ; high blood sugar level ; high level fat blood ; low level HDL cholesterol . Recent study show certain atypical antipsychotic drug relatively weight-neutral . Switching drug promotes weight gain weight-neutral medication , ziprasidone , may result significant weight loss . There insufficient evidence , however , demonstrate extent improvement insulin sensitivity switch medication . This study evaluate effectiveness ziprasidone treatment versus treatment standard atypical antipsychotic drug improve insulin sensitivity reduce excess abdominal fat storage people schizophrenia risk diabetes . Participants open label study currently undergo treatment risperidone olanzapine time study entry . Upon study entry , randomly assign either switch ziprasidone treatment remain current medication . Both group treat 26 week . Participants report study site evaluation biweekly week 10 monthly duration study . The following outcome assess study entry Week 26 : insulin sensitivity , use intravenous glucose tolerance test ; visceral fat mass , use CT scan ; total adiposity , use dexascan .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder Currently receive antipsychotic therapy risperidone olanzapine Overweight Diagnosis diabetes Hospitalization schizophrenia schizoaffective disorder within 90 day prior study entry Refractory schizophrenia schizoaffective disorder Currently receive therapy clozapine No stable residence phone number 90 day prior study entry Prior unsuccessful treatment ziprasidone Intolerance ziprasidone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Ziprasidone</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Insulin Sensitivity</keyword>
	<keyword>Visceral Adiposity</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>